Table 1.
Patient Demographic and Clinical Characteristics
| Characteristic | MyVax (n = 192) |
Control Immunotherapy (n = 95) |
||
|---|---|---|---|---|
| No. | % | No. | % | |
| Age, years | ||||
| < 40 | 26 | 13.5 | 15 | 15.8 |
| 40 to 50 | 60 | 31.3 | 33 | 34.7 |
| 50 to 60 | 56 | 29.2 | 25 | 26.3 |
| ≥ 60 | 50 | 26.0 | 23 | 24.2 |
| Median | 50 | 50 | ||
| Range | 22-80 | 25-80 | ||
| Sex | ||||
| Female | 106 | 55.2 | 51 | 53.7 |
| Male | 86 | 44.8 | 44 | 46.3 |
| ECOG performance status | ||||
| 0 | 135 | 70.3 | 66 | 69.5 |
| 1 | 55 | 28.6 | 27 | 28.4 |
| Not evaluable/missing | 2 | 1.1 | 2 | 2.1 |
| WHO histologic grade | ||||
| Local review | ||||
| 1 | 111 | 57.8 | 59 | 62.1 |
| 2 | 68 | 35.4 | 31 | 32.6 |
| 3 | 12 | 6.3 | 5 | 5.3 |
| Not evaluable/missing | 1 | 0.5 | ||
| Central review | ||||
| 1 | 97 | 50.5 | 49 | 51.6 |
| 2 | 75 | 39.1 | 37 | 38.9 |
| 3 | 13 | 6.8 | 7 | 7.4 |
| Not evaluable/missing | 7 | 3.6 | 2 | 2.1 |
| Ann Arbor disease stage | ||||
| III | 80 | 41.7 | 36 | 37.9 |
| IV | 112 | 58.3 | 59 | 62.1 |
| FLIPI risk group | ||||
| Low | 23 | 12.0 | 6 | 6.3 |
| Intermediate | 100 | 52.1 | 53 | 55.8 |
| High | 67 | 34.9 | 36 | 37.9 |
| Not evaluable/missing | 2 | 1.0 | 0 | 0.0 |
| Bone marrow involvement | 128 | 66.7 | 66 | 69.5 |
| B symptoms | 31 | 16.1 | 17 | 17.9 |
| Bulky disease | 57 | 29.7 | 16 | 16.8 |
| Elevated LDH | 29 | 15.1 | 17 | 17.9 |
| ≥ One extranodal site | 53 | 27.6 | 25 | 26.3 |
| Median duration of watchful waiting, days | 100 | 98 | ||
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase.